Company intelligence / Profile preview
Strike Pharma
Uppsala, Swedenstrikepharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Strike Pharma’s lead programs are in preclinical development. The company has presented data on its ADAC platform and bi-specific antibody candidates at major scientific conferences, demonstrating progress in precision cancer immunotherapy. No clinical results have been reported as of May 2025[2].
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs)Bi-specific antibodiesImmunotherapeutics
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
FyoniBio (cell line development for bi-specific antibody and clinical lead candidate)SciLifeLab Drug Discovery and Development Platform, Uppsala UniversityBIO-X Accelerate Program funding via Swedish Agency for Economic and Regional Growth
Beyond the preview
Go deeper on Strike Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Strike Pharma.